|
|
 Previous Article | Table of Contents | Next Article 
Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome
B Backx, L Broeders and B Lowenberg
Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Erythropoiesis in response to erythropoietin (Epo) in myelodysplastic
syndrome (MDS) in vitro and in vivo is severely impaired. We investigated
the stimulative effect of c-kit ligand (KL) on the erythroid colony-forming
abilities of bone marrow cells from 17 patients with MDS. The effects of
normal donor-derived marrow were examined in comparison. Suppression of
erythroid colony formation in MDS in response to Epo could not be restored
by the addition of interleukin-3 (IL-3) to culture. In cultures dishes
supplemented with KL, erythroid colony formation was dramatically enhanced,
regarding both colony number and size. Colony-forming abilities by MDS
progenitors were improved following costimulation with KL, particularly in
refractory anemia (RA) and refractory anemia with ring sideroblasts (RARS);
however, little enhancement was apparent following KL stimulation of marrow
from patients with refractory anemia with excess of blasts (RAEB),
refractory anemia with excess of blasts in transformation (RAEB-t), and
chronic myelomonocytic leukemia (CMML). These results suggest that KL
responsiveness of patients with low-risk MDS may still be intact, and that
with progression to high-risk MDS, erythroid progenitors lose proliferative
reactivity to both KL and Epo stimulation. KL may have a therapeutic role
in restoring erythropoiesis in a subset of patients with MDS.
Volume 80,
Issue 5,
pp. 1213-1217,
09/01/1992
Copyright © 1992 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Casadevall, P. Durieux, S. Dubois, F. Hemery, E. Lepage, M.-C. Quarre, G. Damaj, S. Giraudier, A. Guerci, G. Laurent, et al.
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial
Blood,
July 15, 2004;
104(2):
321 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-E. Claessens, D. Bouscary, J.-M. Dupont, F. Picard, J. Melle, S. Gisselbrecht, C. Lacombe, F. Dreyfus, P. Mayeux, and M. Fontenay-Roupie
In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis
Blood,
March 1, 2002;
99(5):
1594 - 1601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah
Achievements in Understanding and Treatment of Myelodysplastic Syndromes
Hematology,
January 1, 2000;
2000(1):
110 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg, T. Ahlgren, Y. Beguin, M. Carlsson, J. Carneskog, I. M. Dahl, I. Dybedal, G. Grimfors, L. Kanter-Lewensohn, O. Linder, et al.
Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients
Blood,
July 1, 1998;
92(1):
68 - 75.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Hoefsloot, M. P. van Amelsvoort, L. C.A.M. Broeders, D. C. van der Plas, K. van Lom, H. Hoogerbrugge, I. P. Touw, and B. Lowenberg
Erythropoietin-Induced Activation of STAT5 Is Impaired in the Myelodysplastic Syndrome
Blood,
March 1, 1997;
89(5):
1690 - 1700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
